- Home
- SEED vs APRE Comparison
SEED vs APRE Comparison
Compare SEED & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEED
- APRE
- Stock Information
- Founded
- SEED 1997
- APRE 2006
- Country
- SEED China
- APRE United States
- Employees
- SEED N/A
- APRE N/A
- Industry
- SEED Farming/Seeds/Milling
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SEED Consumer Staples
- APRE Health Care
- Exchange
- SEED Nasdaq
- APRE Nasdaq
- Market Cap
- SEED 10.7M
- APRE 10.0M
- IPO Year
- SEED N/A
- APRE 2019
- Fundamental
- Price
- SEED $1.05
- APRE $1.71
- Analyst Decision
- SEED
- APRE Strong Buy
- Analyst Count
- SEED 0
- APRE 2
- Target Price
- SEED N/A
- APRE $15.50
- AVG Volume (30 Days)
- SEED 67.3K
- APRE 50.9K
- Earning Date
- SEED 06-26-2025
- APRE 08-11-2025
- Dividend Yield
- SEED N/A
- APRE N/A
- EPS Growth
- SEED N/A
- APRE N/A
- EPS
- SEED N/A
- APRE N/A
- Revenue
- SEED $12,910,081.00
- APRE $1,284,475.00
- Revenue This Year
- SEED N/A
- APRE N/A
- Revenue Next Year
- SEED N/A
- APRE N/A
- P/E Ratio
- SEED N/A
- APRE N/A
- Revenue Growth
- SEED 21.51
- APRE 33.27
- 52 Week Low
- SEED $0.98
- APRE $1.41
- 52 Week High
- SEED $4.99
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- SEED 56.42
- APRE 52.34
- Support Level
- SEED $0.98
- APRE $1.48
- Resistance Level
- SEED $1.61
- APRE $1.91
- Average True Range (ATR)
- SEED 0.11
- APRE 0.16
- MACD
- SEED 0.03
- APRE -0.00
- Stochastic Oscillator
- SEED 42.86
- APRE 63.14
About SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.